While GnRH antagonists like relugolix show a potential cardiovascular advantage, this benefit may disappear when patients receive intensive, proactive cardiovascular management. A trial comparing degarelix to Lupron showed no difference in CV toxicity when all patients underwent rigorous CV assessment and optimization, suggesting proactive care is the most critical factor.
Contrary to the common assumption that provider-administered injections ensure superior adherence, real-world data suggests patients on oral ADT (relugolix) are just as, if not more, adherent. This challenges the notion that oral therapies are inherently less reliable for long-term treatment in prostate cancer.
The EMBARC study's "intermittent" arm is misleading. It tested only one treatment-free period, limited to extreme responders who achieved an undetectable PSA. Therapy was then resumed continuously until progression, making it more akin to a trial for metastatic hormone-sensitive disease with a single break, not a model for real-world, multi-cycle intermittent therapy.
The combination of olaparib and radium-223 improves progression-free survival in an unselected patient population. The mechanism isn't reliant on pre-existing BRCA mutations. Instead, radium (an alpha-emitter) induces DNA breaks, and olaparib prevents the PARP enzyme from repairing this new damage, thus sensitizing the tumor to the radiopharmaceutical.
In castration-resistant states, prostate cancer cells often amplify their androgen receptors (AR) to survive low testosterone levels. Bipolar androgen therapy exploits this by introducing a massive surge of testosterone. This "shocks" the over-amplified AR system, causing it to regress and disrupting downstream tumor growth pathways.
In metastatic castration-resistant prostate cancer (MCRPC), PSA levels can be dissociated from radiographic reality. Studies show that ctDNA tumor fraction at baseline and its early kinetic changes are highly prognostic for PFS and OS. This is especially true for treatments like radium, which cause minimal PSA response, making ctDNA a more instructive biomarker.